Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nook and Cranny Investing: Arcos Dorados Holding Inc (ARCO)

Page 1 of 2

Here’s something that should scare you: If the market reverts to its average valuation using finance professor Robert Shiller’s CAPE measure, then the S&P 500 at its current level of earnings should be around 1,100 rather than its current height above 1,500. That’s almost a 30% drop from current levels.

But even if the overall market is overpriced, you can still find opportunities. There are just fewer of them. This is where Jeremy Grantham of investment management firm GMO says to focus: on the nooks and crannies of the market. Think of it as looking under your couch cushions for that spare change among a set of furniture with little else to offer.

Arcos Dorados Holding Inc (NYSE:ARCO)

Just where are these nooks and crannies? Why is everything else potentially so overvalued?

Reasons to fear
Grantham rails against the Federal Reserve’s policy in his recent Q4 letter:

The longer the engineered rates stay below true market rates, the higher asset prices become.  … [Then] a long period of over-investment begins and returns are bid down and everything moves into balance, often helped along if asset prices get too high, as in 2000 and 2007, by a good healthy market crunch. (This strategy will be seen in future years as archetypical of the Greenspan-Bernanke era: badger and bully investors into taking more risk and eventually pushing assets — houses or stocks or both — far over replacement value, followed eventually, at long and hard-to-predict intervals, by exciting crashes….)

He believes the Fed’s low rate policy has distorted markets above their true value. He also mentions that the Fed’s growth predictions are too high, and for an institution that is extremely influential to markets, wrong assumptions will not help develop correct policy.

To add to Grantham’s bearish thoughts, corporate profit margins are at an all-time high, with analysts expecting them to rise even higher in 2014. If corporate profits fall to the historic average and P/E ratios remain constant, stock prices could fall nearly 45%. Add in the potential for natural disasters, like droughts that cost as much as hurricanes, and human disasters, like Congress’ inability to come to a budget resolution and a sticky student debt situation, and there are plenty of reasons to fear where the market at large could end up.

But that’s the perfect time to take cover in nooks and crannies.

Finding winners in a seemingly winless world
Grantham points out some general areas he believes are “only moderately overpriced”: Japan, emerging markets, risky European companies, and forestry and farmland. He fears most other things are “brutally overpriced,” and dislikes fixed income, especially with the risk of inflation.

As I see it, an investor can look at broad-market ETFs to gain exposure to these broad ideas, or pick single companies in these sectors with the potential to outperform. Below are a few ideas I came up with that I believe align with Grantham’s thoughts.

For Japan, the iShares MSCI Japan Index has jumped about 14% over the past three months since the government approved a $100 billion-plus stimulus package. Japan’s Nikkei index trades at a third of what it did during its 1990 bubble, and the demographics of an aging population don’t instill confidence in future growth. But a new government stimulus program might be enough to thwart its economic headwinds.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!